Display options
Cite
Gougeon ML, Poirier-Beaudouin B, Durant J, et al. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon. 2017;3(2):e00245doi: 10.1016/j.heliyon.2017.e00245.
Gougeon, M. L., Poirier-Beaudouin, B., Durant, J., Lebrun-Frenay, C., Saïdi, H., Seffer, V., Ticchioni, M., Chanalet, S., Carsenti, H., Harvey-Langton, A., Laffon, M., Cottalorda, J., Pradier, C., Dellamonica, P., & Vassallo, M. (2017). HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon, 3(2), e00245. https://doi.org/10.1016/j.heliyon.2017.e00245
Gougeon, Marie-Lise, et al. "HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND)." Heliyon vol. 3,2 (2017): e00245. doi: https://doi.org/10.1016/j.heliyon.2017.e00245
Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M. HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND). Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb. PMID: 28224137; PMCID: PMC5310155.
Copy Download .nbib Format: NLM
Share it on

Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).

Heliyon

Marie-Lise Gougeon, Béatrice Poirier-Beaudouin, Jacques Durant, Christine Lebrun-Frenay, Héla Saïdi, Valérie Seffer, Michel Ticchioni, Stephane Chanalet, Helene Carsenti, Alexandra Harvey-Langton, Muriel Laffon, Jacqueline Cottalorda, Christian Pradier, Pierre Dellamonica, Matteo Vassallo

Affiliations

  1. Institut Pasteur, Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, Paris, France.
  2. University of Nice, L'Archet Hospital, Department of Infectious Diseases, Nice, France.
  3. University of Nice, Pasteur Hospital, Department of Neurology, Nice, France.
  4. University of Nice, L'Archet Hospital, Immunology Laboratory Unit, Nice, France.
  5. University of Nice, Pasteur Hospital, Department of Radiology, Nice, France.
  6. University of Nice, L'Archet Hospital, Virology Laboratory Unit, Nice, France.
  7. University of Nice, Department of Public Health, L'Archet Hospital, Nice, France.
  8. University of Nice, L'Archet Hospital, Department of Infectious Diseases, Nice, France; Cannes General Hospital, Department of Internal Medicine, Cannes, France.

PMID: 28224137 PMCID: PMC5310155 DOI: 10.1016/j.heliyon.2017.e00245

Abstract

BACKGROUND: HIV-associated neurocognitive disorders (HAND) persist in the post-HAART era, characterized by asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorders (MND). High mobility group box 1 (HMGB1) is a non-histone chromosomal protein widely expressed in the nucleus of all eukaryotic cells, including brain cells, which acts as a potent proinflammatory cytokine when actively secreted from immune cells. Recent reports suggested that HMGB1 acts on microglial cells to promote neuroinflammation. In this study, our aim was to determine whether HMGB1 is involved in HAND, but also to identify early new markers of neurological impairment in HIV-infected patients.

METHODS: CSF and serum were collected from 103 HIV-1-infected patients enrolled in Neuradapt, a prospective study of the prevalence of HAND in HIV-1 infected patients at Nice University Hospital. Stored fluids were assessed for immunological, virological, and brain metabolite parameters. In addition to HIV RNA and DNA measurements, expression of T-cell surface markers of activation (CD38 and HLA-DR) was analyzed on whole blood. Concentration of 27 cytokines and chemokines was measured using multiplex bead assays on serum and CSF. Concentration of HMGB1 and anti-HMGB1 IgG autoantibodies were also measured on the same samples. Changes in cerebral metabolites N-acetyl aspartate (NAA), Choline (Cho) and creatinine (Cr) were assessed by magnetic resonance microscopy (MRS).

RESULTS: Clinical, virological and immunological characteristics were comparable between HAND (n = 30) and no HAND (n = 73) patients, except the absolute numbers of CD8

CONCLUSION: We report that brain injury in chronically HIV-infected patients on stable HAART is strongly associated with persistent CNS inflammation, which is correlated with increased levels of HMGB1 and anti-HMGB1 IgG in the CSF. Moreover, we identified circulating anti-HMGB1 IgG as a very early biomarker of neurological impairment in patients without HAND. These results might have important implication for the identification of patients who are at high risk of developing neurological disorders.

Keywords: Neuroscience

References

  1. Neuroscience. 1998 Feb;82(4):1021-8 - PubMed
  2. Neurology. 2012 Oct 30;79(18):1873-80 - PubMed
  3. J Leukoc Biol. 2007 Jan;81(1):67-74 - PubMed
  4. FEBS Lett. 2007 May 15;581(10):2017-21 - PubMed
  5. Curr HIV/AIDS Rep. 2014 Sep;11(3):325-35 - PubMed
  6. Neurology. 2014 Jun 10;82(23):2055-62 - PubMed
  7. J Infect Dis. 2007 Dec 15;196(12):1779-83 - PubMed
  8. J Neurovirol. 2013 Aug;19(4):376-82 - PubMed
  9. AIDS. 2007 Jan 30;21(3):283-92 - PubMed
  10. J Neurovirol. 2015 Oct;21(5):559-67 - PubMed
  11. Histol Histopathol. 2014 Feb;29(2):235-42 - PubMed
  12. J Neurochem. 2007 Oct;103(2):590-603 - PubMed
  13. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24 - PubMed
  14. J Neurovirol. 2011 Feb;17(1):3-16 - PubMed
  15. J Neurovirol. 2009 Apr;15(2):111-22 - PubMed
  16. J Leukoc Biol. 2010 Apr;87(4):621-6 - PubMed
  17. Antivir Ther. 2004 Jun;9(3):431-40 - PubMed
  18. Neurology. 1993 Nov;43(11):2245-52 - PubMed
  19. Mol Neurobiol. 2012 Jun;45(3):499-506 - PubMed
  20. J Neurovirol. 2012 Feb;18(1):69-73 - PubMed
  21. Neurology. 2007 Oct 30;69(18):1789-99 - PubMed
  22. J Magn Reson Imaging. 2003 Jun;17(6):625-33 - PubMed
  23. PLoS Pathog. 2010 Jul 29;6(7):e1000937 - PubMed
  24. J Neurosci. 2008 Nov 12;28(46):12023-12031 - PubMed
  25. J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):371-9 - PubMed
  26. AIDS. 2010 Jun 1;24(9):1243-50 - PubMed
  27. PLoS One. 2008 Jun 25;3(6):e2516 - PubMed
  28. HIV Med. 2015 Aug;16(7):431-40 - PubMed
  29. Nat Rev Immunol. 2005 Apr;5(4):331-42 - PubMed
  30. J Leukoc Biol. 2008 Nov;84(5):1248-55 - PubMed
  31. Crit Care Med. 2005 Mar;33(3):564-73 - PubMed
  32. Arthritis Res Ther. 2011 May 06;13(3):R71 - PubMed
  33. PLoS One. 2008;3(10):e3601 - PubMed
  34. Curr HIV/AIDS Rep. 2014 Sep;11(3):336-52 - PubMed
  35. AIDS. 2007 Sep 12;21(14):1915-21 - PubMed
  36. J Leukoc Biol. 2009 Sep;86(3):573-6 - PubMed
  37. HIV Med. 2009 Sep;10(8):504-11 - PubMed
  38. J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35 - PubMed
  39. Anesthesiology. 2014 May;120(5):1160-7 - PubMed
  40. Neurology. 2010 Dec 7;75(23):2087-96 - PubMed
  41. J Exp Med. 2012 Aug 27;209(9):1519-28 - PubMed
  42. J Neurovirol. 2011 Feb;17(1):63-9 - PubMed
  43. PLoS Pathog. 2010 Apr 15;6(4):e1000862 - PubMed
  44. Vaccine. 2009 Feb 18;27(8):1184-91 - PubMed
  45. Neuroimage. 2004 Nov;23(3):928-35 - PubMed
  46. Immunol Rev. 2007 Dec;220:35-46 - PubMed
  47. Cell Death Differ. 2012 Jan;19(1):96-106 - PubMed
  48. Stroke. 2011 May;42(5):1420-8 - PubMed

Publication Types